Compounding group sues FDA over tirzepatide shortage list removal

The Outsourcing Facilities Association sued the U.S. Food and Drug Administration on October 8, 2024, challenging the agency's removal of tirzepatide from the national drug shortage list ^[1].

Tirzepatide is the active ingredient in the brand-name medicines Mounjaro and Zepbound ^[1]. The lawsuit was filed in the Northern District of Texas ^[1]. The association represents 503B outsourcing facilities, a category of FDA-registered compounders that can produce drugs in bulk instead of filling one patient's prescription at a time ^[1].

The filing is an opening step in a case that could shape how much compounded tirzepatide can be made and sold in the United States. The specific legal arguments in the complaint, the relief the association is asking the court for, and whether it has requested an emergency order have not been reported. A public response from the FDA to the lawsuit has also not been reported, and no hearing date or ruling has been announced.

How many facilities make compounded tirzepatide, how many patients use it, and how large that market is have not been disclosed ^[1].

The shortage list is the mechanism the FDA uses to track drugs that are in short supply, and it shapes what compounding pharmacies are allowed to make ^[1]. The FDA removed tirzepatide from the list before the lawsuit was filed, and the association is contesting that decision ^[1]. The FDA has not said publicly why it concluded the shortage had ended, beyond the removal itself, and the agency's reasoning has not been reported in detail.

Why it matters for patients

The practical question for patients is whether compounded tirzepatide stays available. If the FDA's decision stands, large-scale compounding of tirzepatide is expected to wind down; if the association prevails, it could continue. Which way the case goes has not been decided ^[1].

People who get tirzepatide through a compounding pharmacy that buys from a 503B facility could see what their pharmacy can supply change while the case is pending. What happens to prescriptions already being filled, and whether any wind-down period applies before compounding stops, has not been reported.

The lawsuit concerns the shortage list, not the approval of Mounjaro or Zepbound, which remain available as brand-name products ^[1]. The case does not change any individual patient's prescription or the directions from their prescriber.

Any effect on the price of compounded tirzepatide, or on how insurers cover the brand-name versions, has not been reported ^[1].

What happens next

The case is pending in the Northern District of Texas ^[1]. No hearing date has been set, no ruling has been issued, and the FDA's next filing has not been reported. A decision on whether compounding of tirzepatide must stop, or may continue, would come from the court rather than from the agency alone ^[1].